Revista Romana De Medicina De Laborator最新文献_第8页

COVID-19 associated coagulopathy is correlated with increased age and markers of inflammation response COVID-19相关凝血功能障碍与年龄增加和炎症反应标志物相关

IF 0.5 4区医学

Revista Romana De Medicina De Laborator Pub Date : 2021-10-01 DOI: 10.2478/rrlm-2021-0031

Laurențiu Stratan, C. Tilișcan, V. Aramă, M. Lazar, A. Vișan, Oana Ganea, M. I. Trifonescu, S. Aramă, D. Ion

{"title":"COVID-19 associated coagulopathy is correlated with increased age and markers of inflammation response","authors":"Laurențiu Stratan, C. Tilișcan, V. Aramă, M. Lazar, A. Vișan, Oana Ganea, M. I. Trifonescu, S. Aramă, D. Ion","doi":"10.2478/rrlm-2021-0031","DOIUrl":"https://doi.org/10.2478/rrlm-2021-0031","url":null,"abstract":"Abstract Background: The severe manifestations of the coronavirus disease 2019 (COVID-19) are linked to viral hyper-inflammation, cytokine release syndrome and subsequent coagulation disturbances. The most common coagulation abnormality observed in COVID-19 patients is the elevation of the plasma levels of D-dimers. The aim of this study was to evaluate the characteristics of COVID-19-associated inflammatory syndrome and coagulopathy, in correlation with disease severity. Methods: We performed a cross-sectional study, enrolling all consecutive COVID-19 patients treated in the Adulti 3 Department of the Prof. Dr. Matei Bals National Institute of Infectious Diseases, Bucharest, Romania, between 1st march and 30th September 2020. We recorded clinical and epidemiological characteristics, inflammatory markers, coagulation abnormalities and lymphocyte count. The severity of lung involvement was assessed using native Computed Tomography examination. Results: We included 106 patients with SARS-COV2 infection, 50 males (47.2%) and 56 females (52.8%), age range 14-91 years. All markers of inflammation were increased in our study in patients with severe disease, as were lactate dehydrogenase, monocyte distribution width, and neutrophil-to-lymphocyte ratio. An elevated level of serum D-dimers was observed in approximately half of our subjects and was associated with disease severity. Our best linear regression model for predicting COVID-19 coagulopathy (manifested as abnormal D-dimer levels) included age, fibrinogen, and lymphocyte count. Conclusion: Our findings emphasize the association between COVID-19 coagulopathy and the presence of systemic inflammation. A significant proportion of patients with moderate and severe disease had coagulation abnormalities and these were linked with the presence of inflammation and older age..","PeriodicalId":49599,"journal":{"name":"Revista Romana De Medicina De Laborator","volume":"3 1","pages":"387 - 394"},"PeriodicalIF":0.5,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83362504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Agreement between two diagnostic methods for COVID-19: preliminary data from a Brazilian clinical laboratory COVID-19两种诊断方法的一致性:来自巴西临床实验室的初步数据

IF 0.5 4区医学

Revista Romana De Medicina De Laborator Pub Date : 2021-10-01 DOI: 10.2478/rrlm-2021-0026

J. Raimundo, G. Veiga, B. Alves, J. A. Encinas, Marina Cristina Peres, M. Perez, Claudia Giorgia Bronzatti de Oliveira Rodrigues, A. V. Sant'Anna, F. Gehrke, F. Fonseca

{"title":"Agreement between two diagnostic methods for COVID-19: preliminary data from a Brazilian clinical laboratory","authors":"J. Raimundo, G. Veiga, B. Alves, J. A. Encinas, Marina Cristina Peres, M. Perez, Claudia Giorgia Bronzatti de Oliveira Rodrigues, A. V. Sant'Anna, F. Gehrke, F. Fonseca","doi":"10.2478/rrlm-2021-0026","DOIUrl":"https://doi.org/10.2478/rrlm-2021-0026","url":null,"abstract":"Abstract Objective: To investigate possible differences between laboratory profiles of symptomatic and asymptomatic patients. There are different of them available for COVID-19 diagnoses and surveillance, so this research was to evaluate the positive agreement the diagnostic methods. Methods: For symptomatic patients swab samples from nasal and oral mucosal were collected between first and second week after symptoms onset, to perform RT-PCR, blood samples were collected 7 days after to perform antibody detection test. For asymptomatic patients, only antibody detection was performed to confirm the infection. We investigated specific humoral immune response for symptomatic and asymptomatic patients and also analyzed the positivity index and kappa agreement between immunochromatographic and ELISA assays. Results: Most symptomatic patients presented negative RT-PCR with IgM and IgA detection. Symptomatic and asymptomatic patients have presented elevated IgM and IgA immunoglobulins, being this detection higher in symptomatic patients. The positivity index for immunochromatographic was higher than ELISA and there was no kappa agreement between IgM and IgA detection between these two methods. Conclusion: Symptomatic patients presented higher amounts of IgM and IgA than asymptomatic, suggesting a relation between antibody quantity and severity of disease. We verified no agreement between IgM and IgA detection, and observed higher positivity index for IMMUNO when compared to ELISA. The different kinetics may cause a variation in their detection. Also, many different virus proteins can be used as antigens in these methods, being able of altering their sensibility and specificity.","PeriodicalId":49599,"journal":{"name":"Revista Romana De Medicina De Laborator","volume":"60 1","pages":"413 - 420"},"PeriodicalIF":0.5,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74392936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of the impact of Covid-19 infection on the evolution and prognosis of patients with acute leukaemia 新型冠状病毒感染对急性白血病患者病情发展及预后影响的评价

IF 0.5 4区医学

Revista Romana De Medicina De Laborator Pub Date : 2021-10-01 DOI: 10.2478/rrlm-2021-0032

M. Omer, A. Vlădăreanu, V. Popov, M. Andreescu, L. Iliescu, H. Bumbea, Ș. Dragosloveanu

{"title":"Evaluation of the impact of Covid-19 infection on the evolution and prognosis of patients with acute leukaemia","authors":"M. Omer, A. Vlădăreanu, V. Popov, M. Andreescu, L. Iliescu, H. Bumbea, Ș. Dragosloveanu","doi":"10.2478/rrlm-2021-0032","DOIUrl":"https://doi.org/10.2478/rrlm-2021-0032","url":null,"abstract":"Abstract Introduciton: COVID19 is one of the largest pandemics. Since December 2019 until now the coronavirus has infected over 131 million people. The mortality rate in the general population varies between 1 to 5%, with a potential of over 30% in patients with neoplasms. Methods: The main objective of the study was to identify some peculiarities of the evolution, complications and treatment of patients with acute leukaemia and COVID-19. The study was retrospective and included 50 patients with acute leukaemia and COVID-19. Results: Recent administration of chemotherapy was identified in 20 patients with acute myeloblastic leukaemia and 4 patients with acute lymphoblastic leukaemia. The newly diagnosed patients or those undergoing intensive chemotherapy, in particular elderly patients, had a severe form of COVID-19 and an unfavourable evolution, and these clinical situations were identified as predictive factors for adverse outcomes. Patients with acute lymphoblastic leukaemia had a shorter survival curve compared to patients with acute myeloblastic leukaemia. Pneumonia was present especially in patients with acute myeloblastic leukaemia, most patients having over 30% of lung fields affected (55.26%). Patients with an unfavourable outcome had significantly increased median values of C-reactive protein, procalcitonin and interleukin6. Conclusions: Patients with acute leukaemia, especially acute myeloblastic leukaemia who have been diagnosed with COVID-19 infection require special attention because they may associate complications and adverse outcomes of COVID-19. The results we obtained require evaluation in a larger group of patients and analysis in the follow-up period after COVID-19.","PeriodicalId":49599,"journal":{"name":"Revista Romana De Medicina De Laborator","volume":"125 1","pages":"377 - 385"},"PeriodicalIF":0.5,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85877970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Mutations in the KRAS gene as a predictive biomarker of therapeutic response in patients with colorectal cancer KRAS基因突变作为结直肠癌患者治疗反应的预测性生物标志物

IF 0.5 4区医学

Revista Romana De Medicina De Laborator Pub Date : 2021-10-01 DOI: 10.2478/rrlm-2021-0035

D. Jugović, M. Nikolić, Visnja Madic, L. Branković, R. Milićević, G. Stanojevic, P. Vasiljević

{"title":"Mutations in the KRAS gene as a predictive biomarker of therapeutic response in patients with colorectal cancer","authors":"D. Jugović, M. Nikolić, Visnja Madic, L. Branković, R. Milićević, G. Stanojevic, P. Vasiljević","doi":"10.2478/rrlm-2021-0035","DOIUrl":"https://doi.org/10.2478/rrlm-2021-0035","url":null,"abstract":"Abstract Introduction: Despite the important role of general KRAS mutational status in the selection of an adequate therapeutic protocol in patients with colorectal cancer (CRC), studies that focus on its specific mutations and their significance on progression of disease are scarce. This study aimed to determine the significance of specific KRAS mutations in response to standard chemotherapy protocols with oxaliplatin-based (FOLFOX 4, OXFL) in the first-line and irinotecan-based chemotherapy (FOLFIRI, IFL) in the second-line therapy, and to evaluate the correlation between these mutations and clinicopathological characteristics of CRC patients. Methods: Genomic DNA was extracted from the FFPE tumour tissue sections while the KRAS mutation test was performed by using PCR methods. Results: Prevalence of KRAS gene mutations in CRC patients was 45%. Mutated KRAS was more frequent in later stages of tumor infiltrations (P =0.0017), on the right side of the colon (P= 0.0044), and in patients who developed metastases in the first 6 months after CRC diagnosis than in patients who developed metastases after 24 months (P=0.0083). In a group of patients with a poor therapeutic response to standard chemotherapy the most frequent mutations in KRAS gene were G12D and G12V (63.88%), while in a group of patients with a good response to therapeutic protocols the most prevalent mutation was G12A (66.66%). Conclusion: Our results indicate that there was a significant difference in biological behaviour between tumours harboring different mutations in KRAS gene. Overall, mutation G12A could be a novel prognostic biomarker for CRC patients treated with standard chemotherapy.","PeriodicalId":49599,"journal":{"name":"Revista Romana De Medicina De Laborator","volume":"12 1","pages":"365 - 375"},"PeriodicalIF":0.5,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84985097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

VEGF-C and podoplanin, as biomarkers of sepsis. An experimental study VEGF-C和podoplanin作为脓毒症的生物标志物。实验研究

IF 0.5 4区医学

Revista Romana De Medicina De Laborator Pub Date : 2021-10-01 DOI: 10.2478/rrlm-2021-0030

Emőke Almásy, J. Szederjesi, B. Grigorescu, S. Gurzu, A. Lazăr, Gergő Ráduly, A. Man, M. Oprică, Irina Săplăcan, S. Copotoiu

{"title":"VEGF-C and podoplanin, as biomarkers of sepsis. An experimental study","authors":"Emőke Almásy, J. Szederjesi, B. Grigorescu, S. Gurzu, A. Lazăr, Gergő Ráduly, A. Man, M. Oprică, Irina Săplăcan, S. Copotoiu","doi":"10.2478/rrlm-2021-0030","DOIUrl":"https://doi.org/10.2478/rrlm-2021-0030","url":null,"abstract":"Abstract Background: Sepsis is the leading cause of morbidity and mortality in intensive care units. This study explored the possible role of vascular endothelial growth factor-C (VEGF-C) and podoplanin (PDPN) in sepsis. Methods: 22 Wistar rats were divided into three groups: two experimental (Group A and B, n=8/8) and a control (Group C, n=6). Sepsis was induced with intraperitoneal injection of ESBL (extended-spectrum beta-lactamases)-producing E-coli live bacteria for group A and with lipopolysaccharide for group B. Sterile saline solution was injected for group C. Blood samples were collected after 24 hours to determine the serum level of VEGF-C, and PDPN expression was examined in liver, kidney, and lung tissues. Bacteremia was assessed for group A. Results: Higher serum levels of VEGF-C were found in Group A vs C (p=0.05) and group B vs. C (p=0.004), respectively.VEGF-C was also increased in animals with negative- vs. positive blood cultures from group A (p=0.04) and from group B vs. those with positive blood cultures from group A (p=0.03). High intensity of PDPN tissue expression was observed in the pulmonary alveolocytes from Group A and epithelium of the proximal renal tubules in groups B and C, compared to group A. Conclusions: Circulating VEGF-C can be succesfuly used as a biomarker of sepsis with negative blood cultures and high risk of renal failure, whereas PDPN seems to exert a protective role against lung injuries in live bacteria-induced sepsis.","PeriodicalId":49599,"journal":{"name":"Revista Romana De Medicina De Laborator","volume":"16 1","pages":"403 - 412"},"PeriodicalIF":0.5,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90533866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acquired Angioedema Due to C1 inhibitor Deficiency Caused by Non-Hodgkin Lymphoma in a Patient with Myasthenia Gravis 重症肌无力患者非霍奇金淋巴瘤所致C1抑制剂缺乏致后天性血管性水肿1例

IF 0.5 4区医学

Revista Romana De Medicina De Laborator Pub Date : 2021-10-01 DOI: 10.2478/rrlm-2021-0029

N. Bara, V. Nădăşan, L. Varga, H. Farkas

{"title":"Acquired Angioedema Due to C1 inhibitor Deficiency Caused by Non-Hodgkin Lymphoma in a Patient with Myasthenia Gravis","authors":"N. Bara, V. Nădăşan, L. Varga, H. Farkas","doi":"10.2478/rrlm-2021-0029","DOIUrl":"https://doi.org/10.2478/rrlm-2021-0029","url":null,"abstract":"Abstract Acquired angioedema due to C1-inhibitor deficiency is a very rare disorder that usually appears in patients with lymphoproliferative and/or autoimmune diseases. This type of swelling is bradykinin mediated and does not respond to antihistamines, corticosteroids, or epinephrine. The symptoms usually appear in patients older than 40 years with recurrent episodes of angioedema without wheals. The family history is negative. The swelling could affect any tissue, but most frequently is located at the face, lips, tongue, larynx, or extremities. In the gastrointestinal tract, it causes pain, nausea, vomiting, and diarrhea. The upper respiratory airway oedema is a potentially life-threatening condition due to asphyxiation. The oedema attacks may precede the symptoms of the causative disease for months or years. In most cases, the treatment of the underlying disease resolves the angioedema episodes. Here we report a case of C1-INH-AAE caused by non-Hodgkin lymphoma in a patient diagnosed many years before with myasthenia gravis whose angioedema symptoms resolved after the specific treatment of lymphoma.","PeriodicalId":49599,"journal":{"name":"Revista Romana De Medicina De Laborator","volume":"28 1","pages":"453 - 456"},"PeriodicalIF":0.5,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90780494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atellica CH 930 chemistry analyzer versus Cobas 6000 c501 and Architect ci4100 - a multi-analyte method comparison Atellica CH 930化学分析仪与Cobas 6000 c501和Architect ci4100的多分析方法比较

IF 0.5 4区医学

Revista Romana De Medicina De Laborator Pub Date : 2021-10-01 DOI: 10.2478/rrlm-2021-0027

Imola Györfi, Krisztina Pál, I. Mănescu, O. Oprea, M. Dobreanu

{"title":"Atellica CH 930 chemistry analyzer versus Cobas 6000 c501 and Architect ci4100 - a multi-analyte method comparison","authors":"Imola Györfi, Krisztina Pál, I. Mănescu, O. Oprea, M. Dobreanu","doi":"10.2478/rrlm-2021-0027","DOIUrl":"https://doi.org/10.2478/rrlm-2021-0027","url":null,"abstract":"Abstract Large clinical laboratories often rely on multiple chemistry analyzers. However, when a new analyzer is introduced, the laboratory must establish whether the old and new methods are comparable and can be used interchangeably. In this study, we compared the newly introduced Atellica CH930 chemistry analyzer with the already established Architect ci4100 and Cobas 6000 c501 from our laboratory. Patient samples were randomly selected from daily routine testing and a total of 22 analytes were investigated. Total error (TEobs) between test (Atellica) and comparative (Architect and Cobas) methods was calculated at relevant medical decision levels (MDL). For demonstrative purposes, the assessment of method comparability was based on three different criteria: allowable total error (TEa) derived from biological variation (BV), CLIA proficiency testing criteria for acceptable analytical performance, and CLIA-calculated Sigma metrics. These sets of analytical performance specifications were also compared, and their strengths and limitations are discussed in this paper. Performance of Atellica CH930 against Architect ci4100 was acceptable or nearly acceptable at 82%, 95%, and 64% of the 22 investigated MDLs across 9 analytes, according to BV-TEa, CLIA-TEa, and CLIA-calculated Sigma metrics, respectively. Similarly, performance of Atellica CH930 against Cobas 6000 c501 was acceptable or nearly acceptable at 61%, 93%, and 63% of the 54 investigated MDLs across 22 analytes, according to BV-TEa, CLIATEa, and CLIA-calculated Sigma metrics, respectively. However, method comparability should not be evaluated by a “one size fits all” approach as some analytes require different criteria of acceptability, ideally based on medically allowable error and clinical outcome.","PeriodicalId":49599,"journal":{"name":"Revista Romana De Medicina De Laborator","volume":"4 1","pages":"421 - 438"},"PeriodicalIF":0.5,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88213158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Values of serum PCT, suPAR combined with severity scores for evaluating prognosis of septic shock patients 血清PCT、suPAR结合严重程度评分评价脓毒性休克患者预后的价值

IF 0.5 4区医学

Revista Romana De Medicina De Laborator Pub Date : 2021-10-01 DOI: 10.2478/rrlm-2021-0034

Wenxin Wang, Yingxin Jie, Jia Zhou

{"title":"Values of serum PCT, suPAR combined with severity scores for evaluating prognosis of septic shock patients","authors":"Wenxin Wang, Yingxin Jie, Jia Zhou","doi":"10.2478/rrlm-2021-0034","DOIUrl":"https://doi.org/10.2478/rrlm-2021-0034","url":null,"abstract":"Abstract Background: To explore the values of serum procalcitonin (PCT), soluble urokinase-type plasminogen activator receptor (suPAR) combined with APACHE II and SOFA scores for evaluating the prognosis of septic shock patients. Materials and Methods: A total of 118 eligible patients admitted from August 2017 to January 2021 were divided into survival and death groups. Serum PCT and suPAR levels were detected. APACHE II and SOFA scores were evaluated. A combination predictor pre1 was constructed. The predictive efficacy of the indicator alone or in combination was compared using receiver operating characteristic curve. Risk factors leading to death were analyzed, and a predictive model was established. Results: Serum PCT and suPAR levels as well as APACHE II and SOFA scores of death group significantly exceeded those of the survival group (P<0.05). PCT, suPAR, SOFA and APACHE II scores were valuable for predicting death. The area under curve (AUC) constructed by predictor pre1 for predicting death was largest. PCT, suPAR, APACHE II, and SOFA scores were independent risk factors for death. The model had AUC of 0.828, with the sensitivity of 86.54%, specificity of 89.03%, and accuracy of 82.47%. The death risk predicted by the model had a high concurrence with the actual one. Conclusion: PCT, suPAR, APACHE II, and SOFA scores are closely related to the prognosis of septic shock patients. The combined predictor pre1 is more effective than a single index for predicting prognosis. The combined prediction model of septic shock based on PCT, suPAR, APACHE II, and SOFA scores has higher predictive efficiency.","PeriodicalId":49599,"journal":{"name":"Revista Romana De Medicina De Laborator","volume":"19 1","pages":"395 - 402"},"PeriodicalIF":0.5,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82912371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Cell Cycle Regulatory CCND1 G870A Gene Polymorphism and Periodontitis-Induced Oral Cancer: A Risk Analysis 细胞周期调控CCND1 G870A基因多态性与牙周炎诱导的口腔癌:风险分析

IF 0.5 4区医学

Revista Romana De Medicina De Laborator Pub Date : 2021-10-01 DOI: 10.2478/rrlm-2021-0028

M. Khan, Saif Khan, R. Mandal, H. Mahto, M. Lohani, Saheem Ahmad, S. Sherwani, S. Jandrajupalli, S. Haque

{"title":"Cell Cycle Regulatory CCND1 G870A Gene Polymorphism and Periodontitis-Induced Oral Cancer: A Risk Analysis","authors":"M. Khan, Saif Khan, R. Mandal, H. Mahto, M. Lohani, Saheem Ahmad, S. Sherwani, S. Jandrajupalli, S. Haque","doi":"10.2478/rrlm-2021-0028","DOIUrl":"https://doi.org/10.2478/rrlm-2021-0028","url":null,"abstract":"Abstract Strong association has been recently observed between periodontitis/gingivitis and Oral squamous cell carcinoma (OSCC). A high incidence of oral cancer has been reported in the case of chronic periodontitis. Recently Cell cycle regulatory /Senescence genes have been associated with Gingivitis/ Periodontitis susceptibility. Cyclin D1 is one such cell cycle regulatory gene. Several findings have reported that Cyclin D1 (CCND1) G870A Single nucleotide polymorphism is associated with oral cancer (OC) risk, but yielded inconsistent data across different studies. This meta-analysis explores the precise relationship between CCND1 G870A polymorphism and OC risk. PubMed (Medline), EMBASE, & Google Scholar databases were searched for eligible studies and pooled odds ratios (ORs) and 95% confidence intervals (CI) were calculated. Newcastle-Ottawa analysis was done for selected articles quality assessment, bias in publication (if any) was estimated through Funnel plots and Egger’s test. Pooled analysis from eleven eligible studies suggests that CCND1 G870A polymorphism is not significantly associated with OC risk. Sub-group analysis by ethnicity failed to show any association. Sequential single study omission was performed to determine the credibility and resilience of the inferences drawn.","PeriodicalId":49599,"journal":{"name":"Revista Romana De Medicina De Laborator","volume":"29 1","pages":"349 - 363"},"PeriodicalIF":0.5,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79249604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Clinical significance of serum HMGB1 in COPD and correlation with severity of airflow restriction and immune function 慢性阻塞性肺病患者血清HMGB1水平的临床意义及与气流受限严重程度及免疫功能的相关性

IF 0.5 4区医学

Revista Romana De Medicina De Laborator Pub Date : 2021-09-30 DOI: 10.18001/trs.7.5.1.77

Weiguo Xu, Junhua Wu, Yong-Ge Feng, Jing Zhu, R. Cui

{"title":"Clinical significance of serum HMGB1 in COPD and correlation with severity of airflow restriction and immune function","authors":"Weiguo Xu, Junhua Wu, Yong-Ge Feng, Jing Zhu, R. Cui","doi":"10.18001/trs.7.5.1.77","DOIUrl":"https://doi.org/10.18001/trs.7.5.1.77","url":null,"abstract":"Abstract Background: To explore the serum HMGB1 levels in patients with smoking-induced chronic obstructive pulmonary disease (COPD) and the correlations with airflow restriction and immune function. Methods: A total of 136 COPD patients were divided into mild, moderate and severe + extremely severe groups. Thirty-five healthy subjects were selected as control group. Serum HMGB1 levels were measured by ELISA, and the correlations with pulmonary and immune function indices were analyzed. Receiver operating characteristic (ROC) curve was plotted. Results: PaO2, eosinophil count, FEV1/FVC, FEV1% pred, and IgA, IgM, IgG levels of COPD patients were lower than those of control group, and decreased with airflow restriction aggravation. PaCO2, leukocyte count, neutrophil percentage, modified British Medical Research Council (mMRC) scale and COPD Assessment Test (CAT) scores, D-Dimer (D-D), PCT, CRP and HMGB1 levels, myeloid dendritic cell (mDC) and plasmacytoid dendritic cell (pDC) counts, and mDCs/pDCs of COPD patients exceeded those of control group, and increased with airflow restriction aggravation (P<0.05). HMGB1 levels of COPD patients were negatively correlated with FEV1/FVC, FEV1% pred, IgA, IgM and IgG levels and positively correlated with mDC count, pDC count and mDCs/pDCs (P<0.0001). The area under ROC curve was 0.883, the optimal cutoff value was 3.63 ng/mL, and sensitivity and specificity were 86.7% and 85.9%, respectively. Conclusions: Serum HMGB1 level in patients with smoking-induced COPD rises with airflow restriction aggravation and has significant correlations with the decline of pulmonary and immune functions, with high predictive value for COPD. HMGB1 is a potential biomarker for evaluating COPD progression.","PeriodicalId":49599,"journal":{"name":"Revista Romana De Medicina De Laborator","volume":"96 1","pages":"173 - 181"},"PeriodicalIF":0.5,"publicationDate":"2021-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79056993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0